Caitong International Asset Management Co., LTD Astria Therapeutics, Inc. Transaction History
Caitong International Asset Management Co., LTD
- $102 Billion
- Q4 2024
A detailed history of Caitong International Asset Management Co., LTD transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 55 shares of ATXS stock, worth $388. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55
Previous 55
-0.0%
Holding current value
$388
Previous $492,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ATXS
# of Institutions
115Shares Held
51.9MCall Options Held
48KPut Options Held
9.3K-
Perceptive Advisors LLC New York, NY6.49MShares$45.8 Million1.91% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$36 Million0.73% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$29.5 Million2.22% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$25.1 Million6.29% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$24.8 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $107M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...